Volition presents study data at asco gi 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas

Austin, texas, jan. 20, 2022 /prnewswire/ --volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, which show that the company's nu.q® assays, when used in conjunction with the fecal immunochemical test (fit), can detect colorectal cancer and all high-risk advanced adenomas in symptomatic patients, and thereby reduce unnecessary colonoscopies. the studies also demonstrated that the company's nu.q® assays can improve the detection of high-risk adenomas in asymptomatic patients.
VNRX Ratings Summary
VNRX Quant Ranking